Five years after approval by the FDA and EMA, IV Benlysta remains the only drug licensed for the treatment of SLE in almost 60 years, highlighting the difficulty in successfully bringing to market agents to treat this multifactorial disease. Despite the high level of unmet need in SLE, IV Benlysta has seen slow uptake, especially in some European markets, owing to a combination of factors including high price, modest efficacy, low response rate, and slow onset of action. Thus, the level of unmet need in SLE remains high, and significant clinical and commercial opportunities persist for therapies that can provide superior efficacy in reducing disease activity, help to decrease use of corticosteroids, and improve quality of life of patients with SLE.


Related Reports

Systemic Lupus Erythematosus - Landscape & Forecast - Disease Landscape & Forecast

Systemic lupus erythematosus (SLE) is a complex autoimmune disease that can affect nearly any organ or system in the body. As a result, its course,...

View Details

Systemic Lupus Erythematosus - Access & Reimbursement - Detailed, Expanded Analysis (US)

The systemic lupus erythematosus (SLE) therapy market in the United States is largely genericized and off-label. With the exception of GlaxoSmithKline’s Benlysta—which launched in 2011&...

View Details

Systemic Lupus Erythematosus - Current Treatment - Systemic Lupus Erythematosus | Treatment Algorithms: Claims Data Analysis | US | 2020 | Dashboard

MARKET OUTLOOK

View Details

Systemic Lupus Erythematosus - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms - Claims Data Analysis (US) 2020

MARKET OUTLOOK

View Details